JP2022527728A - 成長因子を含有する脱毛治療又は毛髪成長促進用組成物 - Google Patents
成長因子を含有する脱毛治療又は毛髪成長促進用組成物 Download PDFInfo
- Publication number
- JP2022527728A JP2022527728A JP2021544890A JP2021544890A JP2022527728A JP 2022527728 A JP2022527728 A JP 2022527728A JP 2021544890 A JP2021544890 A JP 2021544890A JP 2021544890 A JP2021544890 A JP 2021544890A JP 2022527728 A JP2022527728 A JP 2022527728A
- Authority
- JP
- Japan
- Prior art keywords
- silk
- hair
- composition according
- silk protein
- growth
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 201000004384 Alopecia Diseases 0.000 title claims abstract description 88
- 230000003676 hair loss Effects 0.000 title claims abstract description 56
- 208000024963 hair loss Diseases 0.000 title claims abstract description 56
- 239000003102 growth factor Substances 0.000 title claims abstract description 54
- 230000003779 hair growth Effects 0.000 title claims abstract description 54
- 239000000203 mixture Substances 0.000 title claims abstract description 51
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims abstract description 35
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims abstract description 35
- 230000001737 promoting effect Effects 0.000 claims abstract description 31
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims abstract description 30
- 239000004480 active ingredient Substances 0.000 claims abstract description 16
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims abstract 7
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims abstract 7
- 102000004169 proteins and genes Human genes 0.000 claims description 80
- 108090000623 proteins and genes Proteins 0.000 claims description 80
- 239000002537 cosmetic Substances 0.000 claims description 20
- 239000008194 pharmaceutical composition Substances 0.000 claims description 19
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 18
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 16
- 102000008186 Collagen Human genes 0.000 claims description 12
- 108010035532 Collagen Proteins 0.000 claims description 12
- 229920001436 collagen Polymers 0.000 claims description 12
- MTCFGRXMJLQNBG-UHFFFAOYSA-N serine Chemical compound OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 12
- 102000016942 Elastin Human genes 0.000 claims description 10
- 108010014258 Elastin Proteins 0.000 claims description 10
- 229920002549 elastin Polymers 0.000 claims description 10
- 239000006071 cream Substances 0.000 claims description 9
- 108010022355 Fibroins Proteins 0.000 claims description 8
- 239000004471 Glycine Substances 0.000 claims description 8
- 108010013296 Sericins Proteins 0.000 claims description 8
- -1 byssus Proteins 0.000 claims description 7
- 239000000686 essence Substances 0.000 claims description 7
- 239000000499 gel Substances 0.000 claims description 7
- 239000006210 lotion Substances 0.000 claims description 7
- 239000002674 ointment Substances 0.000 claims description 7
- 239000002552 dosage form Substances 0.000 claims description 6
- 239000000243 solution Substances 0.000 claims description 6
- 239000000443 aerosol Substances 0.000 claims description 5
- 239000003921 oil Substances 0.000 claims description 5
- 239000007921 spray Substances 0.000 claims description 5
- 239000000725 suspension Substances 0.000 claims description 5
- 230000001256 tonic effect Effects 0.000 claims description 5
- 239000002453 shampoo Substances 0.000 claims description 4
- 241001522306 Serinus serinus Species 0.000 claims 4
- 230000003252 repetitive effect Effects 0.000 claims 2
- 230000000694 effects Effects 0.000 abstract description 22
- 230000012010 growth Effects 0.000 abstract description 12
- 230000031774 hair cycle Effects 0.000 abstract description 6
- 206010040880 Skin irritation Diseases 0.000 abstract description 3
- 230000001105 regulatory effect Effects 0.000 abstract description 3
- 230000036556 skin irritation Effects 0.000 abstract description 3
- 231100000475 skin irritation Toxicity 0.000 abstract description 3
- 231100000957 no side effect Toxicity 0.000 abstract description 2
- 230000003658 preventing hair loss Effects 0.000 abstract description 2
- 210000004209 hair Anatomy 0.000 description 54
- 231100000360 alopecia Toxicity 0.000 description 28
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 27
- 108090000385 Fibroblast growth factor 7 Proteins 0.000 description 26
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 26
- 210000004027 cell Anatomy 0.000 description 20
- 238000000034 method Methods 0.000 description 13
- 230000015572 biosynthetic process Effects 0.000 description 12
- 230000003698 anagen phase Effects 0.000 description 9
- 210000004761 scalp Anatomy 0.000 description 8
- 210000003491 skin Anatomy 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 6
- 102000011782 Keratins Human genes 0.000 description 5
- 108010076876 Keratins Proteins 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 238000011084 recovery Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- 206010068168 androgenetic alopecia Diseases 0.000 description 4
- 230000004069 differentiation Effects 0.000 description 4
- 210000003780 hair follicle Anatomy 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 210000000130 stem cell Anatomy 0.000 description 4
- 230000003797 telogen phase Effects 0.000 description 4
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 206010052428 Wound Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 201000002996 androgenic alopecia Diseases 0.000 description 3
- 230000003778 catagen phase Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 210000004207 dermis Anatomy 0.000 description 3
- 230000003176 fibrotic effect Effects 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 229940117382 propecia Drugs 0.000 description 3
- 229940107889 rogaine Drugs 0.000 description 3
- 210000004927 skin cell Anatomy 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 235000015961 tonic Nutrition 0.000 description 3
- 229960000716 tonics Drugs 0.000 description 3
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 2
- 102000003972 Fibroblast growth factor 7 Human genes 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 108010051696 Growth Hormone Proteins 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 102000013275 Somatomedins Human genes 0.000 description 2
- 102100038803 Somatotropin Human genes 0.000 description 2
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 description 2
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 230000003712 anti-aging effect Effects 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 239000012888 bovine serum Substances 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 210000001339 epidermal cell Anatomy 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 229960004039 finasteride Drugs 0.000 description 2
- 239000000122 growth hormone Substances 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 229960003632 minoxidil Drugs 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 229940127557 pharmaceutical product Drugs 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 230000000284 resting effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000036560 skin regeneration Effects 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 1
- ZIMGGGWCDYVHOY-UHFFFAOYSA-N 3-hydroxy-2-imino-6-(1-piperidinyl)-4-pyrimidinamine Chemical compound N=C1N(O)C(N)=CC(N2CCCCC2)=N1 ZIMGGGWCDYVHOY-UHFFFAOYSA-N 0.000 description 1
- 102100032528 C-type lectin domain family 11 member A Human genes 0.000 description 1
- 101710167766 C-type lectin domain family 11 member A Proteins 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 208000017701 Endocrine disease Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000003971 Fibroblast Growth Factor 1 Human genes 0.000 description 1
- 102100031706 Fibroblast growth factor 1 Human genes 0.000 description 1
- 102100037362 Fibronectin Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102100020880 Kit ligand Human genes 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102100027754 Mast/stem cell growth factor receptor Kit Human genes 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 description 1
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 108010039445 Stem Cell Factor Proteins 0.000 description 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001153 anti-wrinkle effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 229940081733 cetearyl alcohol Drugs 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000037319 collagen production Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 208000034557 congenital alopecia Diseases 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000002951 depilatory effect Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- CDMADVZSLOHIFP-UHFFFAOYSA-N disodium;3,7-dioxido-2,4,6,8,9-pentaoxa-1,3,5,7-tetraborabicyclo[3.3.1]nonane;decahydrate Chemical compound O.O.O.O.O.O.O.O.O.O.[Na+].[Na+].O1B([O-])OB2OB([O-])OB1O2 CDMADVZSLOHIFP-UHFFFAOYSA-N 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000008387 emulsifying waxe Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000003721 exogen phase Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 239000007952 growth promoter Substances 0.000 description 1
- 210000002768 hair cell Anatomy 0.000 description 1
- 229940124563 hair growth stimulant Drugs 0.000 description 1
- 230000003660 hair regeneration Effects 0.000 description 1
- 230000003659 hair regrowth Effects 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000036074 healthy skin Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 238000004898 kneading Methods 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 210000004088 microvessel Anatomy 0.000 description 1
- 229940042472 mineral oil Drugs 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 208000030212 nutrition disease Diseases 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000003774 positive effect on hair Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 238000006748 scratching Methods 0.000 description 1
- 230000002393 scratching effect Effects 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940046651 testosterone 40 mg Drugs 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000003762 total hair loss Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 229940099456 transforming growth factor beta 1 Drugs 0.000 description 1
- 230000006459 vascular development Effects 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/65—Collagen; Gelatin; Keratin; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/646—Arachnids, e.g. spiders, scorpions, ticks or mites
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1841—Transforming growth factor [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1858—Platelet-derived growth factor [PDGF]
- A61K38/1866—Vascular endothelial growth factor [VEGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/042—Gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Dermatology (AREA)
- Birds (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Vascular Medicine (AREA)
- Dispersion Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Insects & Arthropods (AREA)
- Cosmetics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
成長因子(VEGF、FGFα、FGFβ、TGF-β、IGF、KGF及びSCF)処理によって細胞のスクラッチが回復するか否かを確認した。
配列番号1:NH2-SGRGGLGGQGAGMAAAAAMGGAGQGGYGGLGSQGT-COOH
5週齢の白鼠(400~500g、Sprague-Dawley系)8匹の背部を完全に除毛するために、毛を剃った後、除毛剤(Mouse removal cream;Veet)を1匹当たり20~30gを塗り、5分後に除毛クリームを拭き取って毛を完全に除去した。毛の除去された部位に、テストステロン40mg/ゲル2g/匹を毎日2週にわたって朝、夕方に2回ずつ塗って脱毛モデリングマウスを作製した。
Claims (28)
- VEGF、FGFα、FGFβ、TGF-β、IGF、KGF及びSCFからなる群から選ばれる成長因子を有効成分として含有する毛髪成長促進又は脱毛抑制用医薬組成物。
- VEGF、FGFα、FGFβ、TGF-β、IGF、KGF及びSCFからなる群から選ばれる2以上の成長因子を含有することを特徴とする、請求項1に記載の医薬組成物。
- シルクタンパク質をさらに含有することを特徴とする、請求項1に記載の医薬組成物。
- 前記シルクタンパク質は、自然由来又は組換えシルクタンパク質から由来したものであることを特徴とする、請求項3に記載の医薬組成物。
- 前記シルクタンパク質は、ドラグラインシルク(dragline silk)、エラスチン(elastin)、シルクフィブロイン(silk fibroin)、バイサス(byssus)、セリシン(sericin)、鞭毛状シルク(flagelliform silk)及びコラーゲン(collagen)からなる群から選ばれるタンパク質を構成する反復単位ペプチドであることを特徴とする、請求項3に記載の医薬組成物。
- 前記シルクタンパク質は、グリシン或いはセリンの含有量が1%以上であるペプチドが1~160回反復されている構造を有することを特徴とする、請求項3に記載の医薬組成物。
- 前記シルクタンパク質は、5~300kDaの分子量を有することを特徴とする、請求項3に記載の医薬組成物。
- エッセンス、シャンプー、クリーム、ローション、トニック、スプレー、エアゾール、オイル、溶液、懸濁液、ゲル及び軟膏からなる群から選ばれる剤形であることを特徴とする、請求項1に記載の医薬組成物。
- VEGF、FGFα、FGFβ、TGF-β、IGF、KGF及びSCFを有効成分として含有する毛髪成長促進又は脱毛抑制用医薬組成物。
- シルクタンパク質をさらに含有することを特徴とする、請求項9に記載の毛髪成長促進又は脱毛抑制用医薬組成物。
- 前記シルクタンパク質は、自然由来又は組換えシルクタンパク質から由来したものであることを特徴とする、請求項10に記載の医薬組成物。
- 前記シルクタンパク質は、ドラグラインシルク(dragline silk)、エラスチン(elastin)、シルクフィブロイン(silk fibroin)、バイサス(byssus)、セリシン(sericin)、鞭毛状シルク(flagelliform silk)及びコラーゲン(collagen)からなる群から選ばれるタンパク質を構成する反復単位ペプチドであることを特徴とする、請求項10に記載の医薬組成物。
- 前記シルクタンパク質は、グリシン或いはセリンの含有量が1%以上であるペプチドが1~160回反復されている構造を有することを特徴とする、請求項10に記載の医薬組成物。
- 前記シルクタンパク質は、5~300kDaの分子量を有することを特徴とする、請求項10に記載の医薬組成物。
- エッセンス、シャンプー、クリーム、ローション、トニック、スプレー、エアゾール、オイル、溶液、懸濁液、ゲル及び軟膏からなる群から選択される剤形であることを特徴とする、請求項9に記載の医薬組成物。
- VEGF、FGFα、FGFβ、TGF-β、IGF、KGF及びSCFからなる群から選ばれる成長因子を有効成分として含有する毛髪成長促進又は脱毛抑制用化粧料組成物。
- VEGF、FGFα、FGFβ、TGF-β、IGF、KGF及びSCFからなる群から選ばれる2以上の成長因子を含有することを特徴とする、請求項16に記載の化粧料組成物。
- シルクタンパク質をさらに含有することを特徴とする、請求項16に記載の化粧料組成物。
- 前記シルクタンパク質は、自然由来又は組換えシルクタンパク質から由来したものであることを特徴とする、請求項18に記載の化粧料組成物。
- 前記シルクタンパク質は、ドラグラインシルク(dragline silk)、エラスチン(elastin)、シルクフィブロイン(silk fibroin)、バイサス(byssus)、セリシン(sericin)、鞭毛状シルク(flagelliform silk)及びコラーゲン(collagen)からなる群から選ばれるタンパク質を構成する反復単位ペプチドであることを特徴とする、請求項18に記載の化粧料組成物。
- 前記シルクタンパク質は、グリシン或いはセリンの含有量が1%以上であるペプチドが1~160回反復されている構造を有することを特徴とする、請求項18に記載の化粧料組成物。
- 前記シルクタンパク質は、5~300kDaの分子量を有することを特徴とする、請求項18に記載の化粧料組成物。
- VEGF、FGFα、FGFβ、TGF-β、IGF、KGF及びSCFを有効成分として含有する毛髪成長促進又は脱毛抑制用化粧料組成物。
- シルクタンパク質をさらに含有することを特徴とする、請求項23に記載の毛髪成長促進又は脱毛抑制用化粧料組成物。
- 前記シルクタンパク質は、自然由来又は組換えシルクタンパク質から由来したものであることを特徴とする、請求項24に記載の化粧料組成物。
- 前記シルクタンパク質は、ドラグラインシルク(dragline silk)、エラスチン(elastin)、シルクフィブロイン(silk fibroin)、バイサス(byssus)、セリシン(sericin)、鞭毛状シルク(flagelliform silk)及びコラーゲン(collagen)からなる群から選ばれるタンパク質を構成する反復単位ペプチドであることを特徴とする、請求項24に記載の化粧料組成物。
- 前記シルクタンパク質は、グリシン或いはセリンの含有量が1%以上であるペプチドが1~160回反復されている構造を有することを特徴とする、請求項24に記載の化粧料組成物。
- 前記シルクタンパク質は、5~300kDaの分子量を有することを特徴とする、請求項24に記載の化粧料組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020200029994A KR20210114646A (ko) | 2020-03-11 | 2020-03-11 | 성장인자를 함유하는 탈모 치료 또는 모발 성장 촉진용 조성물 |
KR10-2020-0029994 | 2020-03-11 | ||
PCT/KR2021/002969 WO2021182866A1 (ko) | 2020-03-11 | 2021-03-10 | 성장인자를 함유하는 탈모 치료 또는 모발 성장 촉진용 조성물 |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2022527728A true JP2022527728A (ja) | 2022-06-06 |
Family
ID=77671772
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021544890A Pending JP2022527728A (ja) | 2020-03-11 | 2021-03-10 | 成長因子を含有する脱毛治療又は毛髪成長促進用組成物 |
Country Status (8)
Country | Link |
---|---|
US (1) | US20230363999A1 (ja) |
EP (1) | EP3903807A4 (ja) |
JP (1) | JP2022527728A (ja) |
KR (1) | KR20210114646A (ja) |
CN (1) | CN113660947A (ja) |
AU (1) | AU2021209267A1 (ja) |
SG (1) | SG11202108253PA (ja) |
WO (1) | WO2021182866A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117143256B (zh) * | 2023-10-27 | 2024-01-26 | 英特菲尔(成都)生物制品有限责任公司 | 一种用于毛发修护的细胞外基质蛋白及其制备方法与应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100802144B1 (ko) * | 2007-01-24 | 2008-02-14 | (주)쉐르본 | 탈모 방지 또는 모발성장 촉진용 조성물 |
KR20170008501A (ko) * | 2015-07-14 | 2017-01-24 | (주)피앤피바이오팜 | 모낭 세포의 재생과 성장을 촉진하는 성장인자, 고안정성 섬유아세포 성장인자 변이체 및 노긴 펩타이드를 함유한 헤어케어 화장품 조성물 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4596812A (en) | 1976-05-24 | 1986-06-24 | The Upjohn Company | Methods and solutions for treating male pattern alopecia |
US4139619A (en) | 1976-05-24 | 1979-02-13 | The Upjohn Company | 6-Amino-4-(substituted amino)-1,2-dihydro-1-hydroxy-2-iminopyrimidine, topical compositions and process for hair growth |
JPH04224522A (ja) * | 1990-04-27 | 1992-08-13 | Merck & Co Inc | 繊維芽細胞増殖因子含有組成物による禿頭症の治療又は予防方法 |
SK281674B6 (sk) * | 1993-03-26 | 2001-06-11 | Amgen Inc. | Farmaceutická kompozícia na stimuláciu hepatocytov, pneumocytov typu ii, pohárikovitých buniek produkujúcich mucín a iných epitelových buniek |
KR100796817B1 (ko) * | 2005-03-23 | 2008-01-22 | 정용지 | 모발과 피부의 치료를 위한 성장인자 |
US20080193386A1 (en) | 2005-03-24 | 2008-08-14 | Medigenes Co., Ltd | Compositions for Treating Alopecia or Promoting Hair Growth |
US20070224150A1 (en) * | 2005-03-24 | 2007-09-27 | Yongji Chung | Growth factor for hair and skin treatment |
JP5389334B2 (ja) * | 2007-03-15 | 2014-01-15 | セーレン株式会社 | 血管内皮細胞増殖因子産生促進剤および育毛養毛用皮膚外用剤 |
KR101317420B1 (ko) | 2010-03-11 | 2013-10-10 | 한국과학기술원 | 고분자량의 재조합 실크 또는 실크 유사 단백질 및 이를 이용하여 제조된 마이크로 또는 나노 크기의 거미줄 또는 거미줄 유사 섬유 |
DK2797609T3 (en) * | 2011-12-30 | 2017-01-09 | Innomed S A | COMBINING growth factors, cytokines, anti-bacterial / ANTIVIRALS FACTORS STEM CELL-STIMULATING FACTORS, complement C3A / C4A, immunoglobulins, and chemotactic factors |
CN109908329A (zh) * | 2019-04-02 | 2019-06-21 | 北京中农创新生物工程研究院有限公司 | 毛囊细胞激活因子止脱生发制剂生产工艺及其用途 |
-
2020
- 2020-03-11 KR KR1020200029994A patent/KR20210114646A/ko not_active IP Right Cessation
-
2021
- 2021-03-10 WO PCT/KR2021/002969 patent/WO2021182866A1/ko unknown
- 2021-03-10 JP JP2021544890A patent/JP2022527728A/ja active Pending
- 2021-03-10 EP EP21742294.8A patent/EP3903807A4/en active Pending
- 2021-03-10 US US17/427,082 patent/US20230363999A1/en active Pending
- 2021-03-10 CN CN202180002250.7A patent/CN113660947A/zh active Pending
- 2021-03-10 AU AU2021209267A patent/AU2021209267A1/en active Pending
- 2021-03-10 SG SG11202108253P patent/SG11202108253PA/en unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100802144B1 (ko) * | 2007-01-24 | 2008-02-14 | (주)쉐르본 | 탈모 방지 또는 모발성장 촉진용 조성물 |
KR20170008501A (ko) * | 2015-07-14 | 2017-01-24 | (주)피앤피바이오팜 | 모낭 세포의 재생과 성장을 촉진하는 성장인자, 고안정성 섬유아세포 성장인자 변이체 및 노긴 펩타이드를 함유한 헤어케어 화장품 조성물 |
Non-Patent Citations (1)
Title |
---|
JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY, 2018. VOL.48, P.128-136, JPN6022030840, ISSN: 0004989585 * |
Also Published As
Publication number | Publication date |
---|---|
EP3903807A4 (en) | 2022-10-05 |
WO2021182866A1 (ko) | 2021-09-16 |
CN113660947A (zh) | 2021-11-16 |
US20230363999A1 (en) | 2023-11-16 |
AU2021209267A1 (en) | 2021-10-07 |
KR20210114646A (ko) | 2021-09-24 |
EP3903807A1 (en) | 2021-11-03 |
SG11202108253PA (en) | 2021-10-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7351404B2 (en) | Method of enhancing hair growth | |
JPH04224522A (ja) | 繊維芽細胞増殖因子含有組成物による禿頭症の治療又は予防方法 | |
JP7315675B2 (ja) | 脱毛治療又は毛髪成長促進用の組成物 | |
KR102535575B1 (ko) | 고안정성 섬유아세포 성장인자-9 변이체를 유효성분으로 포함하는 헤어케어 화장품 조성물 | |
JP2008534494A (ja) | 脱毛治療または毛髪成長促進用の組成物 | |
JP2022527728A (ja) | 成長因子を含有する脱毛治療又は毛髪成長促進用組成物 | |
JP2014506586A (ja) | 化学療法及び放射線療法によって惹起される脱毛症(cria)を予防し、criaの衝撃を低減し、及びcria後の毛髪の再成長の出現を改善するための組成物の新規な使用 | |
JPH02502818A (ja) | 遺伝性脱毛症を治療するためのミノキシジルおよび抗炎症剤の組合わせ | |
JP7135106B2 (ja) | 頭皮頭髪用組成物 | |
US20160151274A1 (en) | Use of gingival fibroblasts in the treatment of alopecia | |
US20230144955A1 (en) | Peptide for preventing or treating hair loss, and use thereof | |
KR102238748B1 (ko) | 섬유아세포 배양액을 포함하는 발모 촉진 또는 탈모 치료용 조성물 | |
JP2009091325A (ja) | 育毛剤 | |
Trilisnawati et al. | Update treatment of male androgenetic alopecia | |
JPH0725652B2 (ja) | 新規な頭皮向け美髪用組成物 | |
TWI476010B (zh) | 促進毛髮生長之組合物 | |
US20230023847A1 (en) | Composition for preventing hair loss and promoting hair regrowth | |
JPH07330555A (ja) | 育毛剤 | |
CN114366687A (zh) | 齐酞酸在促进毛发生长中的应用 | |
KR20210076494A (ko) | 트롬보포이에틴을 포함하는 탈모 방지 또는 발모 촉진용 조성물 | |
AU2012261499A1 (en) | Method of enhancing hair growth |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210917 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220726 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20221026 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20221130 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20230214 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230614 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20230614 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20230727 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20230901 |